BibTex RIS Cite

A Case with Thrombocytopenia Developing after Tirofiban Treatment

Year 2010, Volume: 17 Issue: 1, 55 - 57, 01.02.2010

Nusret Açıkgöz Necip Ermiş Mehmet Cansel Jülide Yağmur Hasan Pekdemir Ramazan Özdemir

Abstract

Platelets have a central role in many cardiovascular events. Tirofiban is a glycoprotein (GP) IIb/IIIa receptor inhibitor that prevents platelet aggregation. In this report, it was aimed to review the thrombocytopenia induced by tirofiban treatment and other causes of thrombocytopenia. Key words: Tirofiban, Thrombocytopenia, GP IIb/IIIa İnhibitors

Keywords

Tirofiban Thrombocytopenia GP IIb/IIIa İnhibitors

References

  • Boersma E, Harrington EA, Moliterno DJ, White H, Simoons ML. Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a metaanalysis of all major randomised clinical trials. Lancet 2002;359(9302):189-98.
  • Karvouni E, Katritsis DG, Ioannidis JP. Intravenous glycoprotein IIb/IIIa receptor antagonists reduce mortality after percutaneous coronary interventions. J Am Coll Cardiol 2003;41:26-32.
  • Özmen F, Atalar E, Özer N. Akut koroner sendromda trombositler ve glikoprotein IIb/IIIa inhibitörleri. Türk J Cardiol 2007;10:91-100.
  • Abrams CS, Cines DB. Thrombocytopenia after treatment with platelet glycoprotein IIb/IIIa inhibitors. Curr Hematol Rep 2004;3:143-47.
  • Aster RH. Drug-induced immune thrombocytopenia: an overview of pathogenesis. Semin Hematol 1999;362-66.
  • Holmes MB, Kabbani S, Watkins M, Battle RW, Schneider DJ. Abciximab associated pseudothrombocytopenia. Circulation 2000;101:938–39.
  • Warkentin TE, Aird WC, Rand JH. Platelet-endothelial intereactions: sepsis, HIT and antiphospholipid syndrome. Hematology 2003;497-519.
  • Bougie DW, Wilker PR, Wuitschick ED, Curtis BR, Malik M, Levine S, Lind RN, Pereira J, Aster RH. Acute thrombocytopenia after treatment with tirofiban or eptifibatide Thrombocytopenia after tirofiban is associated with antibodies specific for ligand- occupied GPIIb/IIIa. Blood 2002;100:2071-6.
  • Curtis B, Swyers J, Divgi A, McFarland J, Aster R. Thrombocytopenia after second exposure to abciximab is caused by antibodies that recognize abciximab coated platelets. Blood 2002;99:2054-9.
  • Tirofiban Tedavisi Sonrası Gelişen Trombositopeni Olgusu
  • Eryonucu B, Tuncer M, Erkoc R. Repetitive profound thrombocytopenia after treatment with tirofiban: a case report. Cardiovasc Drugs Therapy 2004;18:503-5.
  • Demirkan B, Guray Y, Guray U, Korkmaz S. Differential diagnosis and management of acute profound thrombocytopenia by tirofiban: a case report. J Thromb Thrombolysis 2006;22:77-8.
  • Beiras-Fernandez A, Kowert A, Jiru P, Weis M, Spannagl M, Reichart B, Schmoeckel M. Acute profound thrombocytopenia after treatment with tirofiban and off-pump coronary artery bypass grafting. Ann Thorac Surg 2009;87(2):629-31.

Tirofiban Tedavisi Sonrası Gelişen Trombositopeni Olgusu

Year 2010, Volume: 17 Issue: 1, 55 - 57, 01.02.2010

Nusret Açıkgöz Necip Ermiş Mehmet Cansel Jülide Yağmur Hasan Pekdemir Ramazan Özdemir

Abstract

Trombositler birçok kardiyovasküler olayda merkezi role sahiptirler. Tirofiban, trombosit agregasyonunu önleyen bir glikoprotein (GP) IIb/IIIa reseptör inhibitörüdür. Bu olguda tirofiban tedavisi sonrası gelişen trombositopeni ve trombositopeni yapan diğer nedenlerin gözden geçirilmesi amaçlandı. Anahtar kelimeler: Tirofiban, Trombositopeni, GP IIb/IIIa İnhibitörleri

Keywords

Tirofiban Trombositopeni GP IIb/IIIa İnhibitörleri

References

  • Boersma E, Harrington EA, Moliterno DJ, White H, Simoons ML. Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a metaanalysis of all major randomised clinical trials. Lancet 2002;359(9302):189-98.
  • Karvouni E, Katritsis DG, Ioannidis JP. Intravenous glycoprotein IIb/IIIa receptor antagonists reduce mortality after percutaneous coronary interventions. J Am Coll Cardiol 2003;41:26-32.
  • Özmen F, Atalar E, Özer N. Akut koroner sendromda trombositler ve glikoprotein IIb/IIIa inhibitörleri. Türk J Cardiol 2007;10:91-100.
  • Abrams CS, Cines DB. Thrombocytopenia after treatment with platelet glycoprotein IIb/IIIa inhibitors. Curr Hematol Rep 2004;3:143-47.
  • Aster RH. Drug-induced immune thrombocytopenia: an overview of pathogenesis. Semin Hematol 1999;362-66.
  • Holmes MB, Kabbani S, Watkins M, Battle RW, Schneider DJ. Abciximab associated pseudothrombocytopenia. Circulation 2000;101:938–39.
  • Warkentin TE, Aird WC, Rand JH. Platelet-endothelial intereactions: sepsis, HIT and antiphospholipid syndrome. Hematology 2003;497-519.
  • Bougie DW, Wilker PR, Wuitschick ED, Curtis BR, Malik M, Levine S, Lind RN, Pereira J, Aster RH. Acute thrombocytopenia after treatment with tirofiban or eptifibatide Thrombocytopenia after tirofiban is associated with antibodies specific for ligand- occupied GPIIb/IIIa. Blood 2002;100:2071-6.
  • Curtis B, Swyers J, Divgi A, McFarland J, Aster R. Thrombocytopenia after second exposure to abciximab is caused by antibodies that recognize abciximab coated platelets. Blood 2002;99:2054-9.
  • Tirofiban Tedavisi Sonrası Gelişen Trombositopeni Olgusu
  • Eryonucu B, Tuncer M, Erkoc R. Repetitive profound thrombocytopenia after treatment with tirofiban: a case report. Cardiovasc Drugs Therapy 2004;18:503-5.
  • Demirkan B, Guray Y, Guray U, Korkmaz S. Differential diagnosis and management of acute profound thrombocytopenia by tirofiban: a case report. J Thromb Thrombolysis 2006;22:77-8.
  • Beiras-Fernandez A, Kowert A, Jiru P, Weis M, Spannagl M, Reichart B, Schmoeckel M. Acute profound thrombocytopenia after treatment with tirofiban and off-pump coronary artery bypass grafting. Ann Thorac Surg 2009;87(2):629-31.
There are 13 citations in total.

Details

Primary Language Turkish
Journal Section Articles
Authors

Nusret Açıkgöz This is me

Necip Ermiş This is me

Mehmet Cansel This is me

Jülide Yağmur This is me

Hasan Pekdemir This is me

Ramazan Özdemir This is me

Publication Date February 1, 2010
Published in Issue Year 2010 Volume: 17 Issue: 1

Cite

APA Açıkgöz, N., Ermiş, N., Cansel, M., Yağmur, J., et al. (2010). Tirofiban Tedavisi Sonrası Gelişen Trombositopeni Olgusu. Journal of Turgut Ozal Medical Center, 17(1), 55-57.
AMA Açıkgöz N, Ermiş N, Cansel M, Yağmur J, Pekdemir H, Özdemir R. Tirofiban Tedavisi Sonrası Gelişen Trombositopeni Olgusu. J Turgut Ozal Med Cent. February 2010;17(1):55-57.
Chicago Açıkgöz, Nusret, Necip Ermiş, Mehmet Cansel, Jülide Yağmur, Hasan Pekdemir, and Ramazan Özdemir. “Tirofiban Tedavisi Sonrası Gelişen Trombositopeni Olgusu”. Journal of Turgut Ozal Medical Center 17, no. 1 (February 2010): 55-57.
EndNote Açıkgöz N, Ermiş N, Cansel M, Yağmur J, Pekdemir H, Özdemir R (February 1, 2010) Tirofiban Tedavisi Sonrası Gelişen Trombositopeni Olgusu. Journal of Turgut Ozal Medical Center 17 1 55–57.
IEEE N. Açıkgöz, N. Ermiş, M. Cansel, J. Yağmur, H. Pekdemir, and R. Özdemir, “Tirofiban Tedavisi Sonrası Gelişen Trombositopeni Olgusu”, J Turgut Ozal Med Cent, vol. 17, no. 1, pp. 55–57, 2010.
ISNAD Açıkgöz, Nusret et al. “Tirofiban Tedavisi Sonrası Gelişen Trombositopeni Olgusu”. Journal of Turgut Ozal Medical Center 17/1 (February 2010), 55-57.
JAMA Açıkgöz N, Ermiş N, Cansel M, Yağmur J, Pekdemir H, Özdemir R. Tirofiban Tedavisi Sonrası Gelişen Trombositopeni Olgusu. J Turgut Ozal Med Cent. 2010;17:55–57.
MLA Açıkgöz, Nusret et al. “Tirofiban Tedavisi Sonrası Gelişen Trombositopeni Olgusu”. Journal of Turgut Ozal Medical Center, vol. 17, no. 1, 2010, pp. 55-57.
Vancouver Açıkgöz N, Ermiş N, Cansel M, Yağmur J, Pekdemir H, Özdemir R. Tirofiban Tedavisi Sonrası Gelişen Trombositopeni Olgusu. J Turgut Ozal Med Cent. 2010;17(1):55-7.